



# Extreme depletion of PIP<sub>3</sub> accompanies the increased life span and stress tolerance of PI3K-null *C. elegans* mutants

Puneet Bharill<sup>1,2†</sup>, Srinivas Ayyadevara<sup>1,3</sup>, Ramani Alla<sup>1,3</sup> and Robert J. Shmookler Reis<sup>1,2,3\*</sup>

<sup>1</sup> McClellan VA Medical Center, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA

<sup>2</sup> Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

<sup>3</sup> Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA

## Edited by:

Elena G. Pasyukova, Institute of Molecular Genetics of Russian Academy of Sciences, Russia

## Reviewed by:

Yelena V. Budovskaya, University of Amsterdam, Netherlands  
Brian Kraemer, VA Puget Sound Health Care System, USA

## \*Correspondence:

Robert J. Shmookler Reis, Veterans Affairs Medical Center, 4300 West 7th Street, Little Rock, AR 72205, USA.  
e-mail: rjsr@uams.edu

## †Present address:

Puneet Bharill, Department 2 of Internal Medicine, Systems Biology of Aging, Center for Molecular Medicine, University of Cologne, Cologne, Germany.

The regulation of animal longevity shows remarkable plasticity, in that a variety of genetic lesions are able to extend lifespan by as much as 10-fold. Such studies have implicated several key signaling pathways that must normally limit longevity, since their disruption prolongs life. Little is known, however, about the proximal effectors of aging on which these pathways are presumed to converge, and to date, no pharmacologic agents even approach the life-extending effects of genetic mutation. In the present study, we have sought to define the downstream consequences of *age-1* nonsense mutations, which confer 10-fold life extension to the nematode *Caenorhabditis elegans* – the largest effect documented for any single mutation. Such mutations insert a premature stop codon upstream of the catalytic domain of the AGE-1/p110 $\alpha$  subunit of class-I PI3K. As expected, we do not detect class-I PI3K (and based on our sensitivity, it constitutes <14% of wild-type levels), nor do we find any PI3K activity as judged by immunodetection of phosphorylated AKT, which strongly requires PIP<sub>3</sub> for activation by upstream kinases, or immunodetection of its product, PIP<sub>3</sub>. In the latter case, the upper 95%-confidence limit for PIP<sub>3</sub> is 1.4% of the wild-type level. We tested a variety of commercially available PI3K inhibitors, as well as three phosphatidylinositol analogs (PIAs) that are most active in inhibiting AKT activation, for effects on longevity and survival of oxidative stress. Of these, GDC-0941, PIA6, and PIA24 (each at 1 or 10  $\mu$ M) extended lifespan by 7–14%, while PIAs 6, 12, and 24 (at 1 or 10  $\mu$ M) increased survival time in 5 mM peroxide by 12–52%. These effects may have been conferred by insulinlike signaling, since a reporter regulated by the DAF-16/FOXO transcription factor, SOD-3::GFP, was stimulated by these PIAs in the same rank order (PIA24 > PIA6 > PIA12) as lifespan. A second reporter, PEPCCK::GFP, was equally activated (~40%) by all three.

**Keywords:** insulin signaling, IGF-1, longevity, oxidative stress, PI3K, phosphatidylinositides, *C. elegans*/nematode

## INTRODUCTION

Phosphatidylinositides are tightly regulated signaling molecules that participate in a diverse range of cellular events, including cell replication and survival, membrane trafficking, secretion, adhesion, and cell migration (Boss and Im, 2012; Echard, 2012; Mayinger, 2012). Phosphatidylinositol (PI; sometimes abbreviated as “PtdIns”) lipid chains are generally integrated into inner cell membranes, while the attached phosphoinositide rings project into the cytoplasm. PI’s are formed by additions of phosphate to hydroxyl groups at the 1, 3, 4, and/or 5 position of the inositol ring. Additions at the 3 position are governed by phosphatidylinositol 3-kinases (PI3K’s), enzymes with key regulatory roles in cell division and metabolism (Wymann and Schultz, 2012). Class-I PI3K’s convert PI(4,5)P<sub>2</sub> (often abbreviated as PIP<sub>2</sub>) to PI(3,4,5)P<sub>3</sub> (or PIP<sub>3</sub>), which plays decisive roles in multiple signaling pathways.

Intracellular concentrations of L- $\alpha$  phosphatidylinositol 4,5-bisphosphate (known as PI(4,5)P<sub>2</sub>, one of several PIP<sub>2</sub> isoforms) lie in the range of 2–30  $\mu$ M (Gambhir et al., 2004). Class-I phosphatidylinositol 3-kinase (PI3K) can add phosphate to PI(4,5)P<sub>2</sub> at the inositol 3 carbon to form phosphatidylinositol

3,4,5-triphosphate [PI(3,4,5)P<sub>3</sub> or PIP<sub>3</sub>]. This key signaling molecule or “second messenger” is normally present at only ~0.1% of the levels of its precursor (Weinkove et al., 2006), or <30 nM. In response to stimuli, however, the concentration of PIP<sub>3</sub> can increase up to 100-fold (Pettitt et al., 2006), achieved through activation of PI3K and/or inactivation of the opposing PI 3-phosphatase, PTEN. Many membrane-associated proteins, including a number of kinases involved in signal transduction cascades, have a domain that binds either PIP<sub>3</sub> or a specific PIP<sub>2</sub>. The best-studied of these are Pleckstrin Homology (PH) domains, typically ~120 amino-acid residues long, many of which show quite specific affinity for PIP<sub>3</sub>. In the insulin signaling pathway, formation of PIP<sub>3</sub> is required for the downstream activation of AKT/PKB, a protein kinase that promotes cell proliferation and blocks apoptosis in many cell types (Franke et al., 1997). In order to be activated, AKT must bind PIP<sub>3</sub> at its PH domain. This tethers AKT to the inner cell membrane, in relative proximity to its upstream kinase(s) and downstream targets, while also inducing a structural change in AKT to expose a key phosphorylation site to activating kinases such as PDK-1 (Stokoe et al., 1997). Mammalian AKTs are fully active when phosphorylated at residues Thr<sup>308</sup> and Ser<sup>473</sup> (Stokoe et al.,

1997); other AKT-activating kinases include DNA-dependent protein kinase (DNA-PK) (Dragoi et al., 2005; Sester et al., 2006) and TOR complex (Hawkins et al., 2006). Following dimerization, AKT1/AKT2 complex phosphorylates dozens of targets, including kinases and transcription factors, leading to their activation or inactivation (Cutillas et al., 2006). FOXO transcription factors (DAF-16 isoforms in *Caenorhabditis elegans*) are among the inactivated targets, as their phosphorylation by the AKT complex prevents their entry into the nucleus (Tissenbaum and Ruvkun, 1998; Berdichevsky et al., 2006). AKT mutations conferring constitutive activation are observed in many cancers (Shtilbans et al., 2008); mutations in the *pten* gene, disrupting the PI 3-phosphatase that opposes PI3K, also produce a high PIP<sub>3</sub>/PIP<sub>2</sub> ratio, favoring activated AKT and hence cell proliferation in diverse cancers (Yi et al., 2005). Although direct constitutive activation of PI3K is far less common, the BCR-ABL fusion protein indirectly activates PI3K, thus elevating PIP<sub>3</sub> in chronic myelogenous leukemia (Kharas et al., 2008).

The above findings demonstrate the critical involvement of PIP<sub>3</sub>/AKT/FOXO signaling in cell proliferation, and have led to great interest in disruption of such signaling in cancers (Castillo et al., 2004). However, this kinase cascade has also been implicated in other roles beyond cell proliferation. Enhanced PIP<sub>3</sub> signaling in specific hypothalamic neurons is associated with diet-sensitive obesity (Plum et al., 2006). Lithium, commonly used as a mood stabilizer for bipolar disorder, suppresses PIP<sub>3</sub> signaling in *Dicotyledonium* and in cultured human cells (King et al., 2009). To date, attention has been largely focused on drugs that target PI3K or AKT. The two PI3K inhibitors in most common use are LY294002 and wortmannin (Vlahos et al., 1994; Schultz et al., 1995; Semba et al., 2002). These drugs bind to the ATP-binding site of PI3K, LY294002 reversibly (IC<sub>50</sub> 0.5–10 μM) and wortmannin much more avidly (IC<sub>50</sub> 7 nM) (Wu et al., 2008). Both are known to inhibit other kinases (e.g., PLK1) with similar IC<sub>50</sub> values; in view of the thousands of proteins with ATP-binding sites, such off-target effects are not surprising. A number of PI3K inhibitors have been developed through small-molecule screens or by synthetic chemistry testing derivatives of partially effective molecules. Among these, ZSTK474 inhibits p110γ somewhat more than α or β (IC<sub>50</sub>'s of 6, 17, and 53 nM respectively); whereas A66 is rather specific for p110α (IC<sub>50</sub> of 32 nM), requiring >3 μM to reach the IC<sub>50</sub> against β or γ. The most avid p110α inhibitor is GDC-0941 with an IC<sub>50</sub> of 3 nM, but its activity against other PI3K isoforms has not been reported. In another approach, phosphatidylinositol analogs (PIAs) were designed to dock in the PIP<sub>3</sub>-binding (PH) domain of AKT and thereby inhibit its activity (Kozikowski et al., 2003). It is not known whether any of these compounds have affinity for the PIP<sub>2</sub>-binding catalytic site of PI3K.

The *C. elegans age-1* gene encodes the nematode homolog of p110α, the mammalian class-I or -Iα catalytic subunit of PI3K (Morris et al., 1996) responsible for conversion of PIP<sub>2</sub> to PIP<sub>3</sub>. Nonsense mutants of *age-1*, at the second homozygous generation, should lack any active PI3K. These worms are extremely long-lived and resistant to multiple stresses; they develop very slowly and are completely infertile, reflecting severely impaired cell division (Ayyadevara et al., 2008). Those phenotypes were largely blunted in the first homozygous generation, presumably

due to carry-over of oocyte PI3K, *age-1* mRNA, or PIP<sub>3</sub> from their *age-1*-heterozygous parent.

Because PIP<sub>3</sub> can allosterically alter the conformation of a PH-domain protein, permitting its activation by one or more kinases, PIP<sub>3</sub> may serve as a catalyst for that activation and be required only in minute amounts. In contrast, it is required continuously (and hence stoichiometrically) for its membrane-tethering role. We therefore predict that, over most of its physiological range of concentration, PIP<sub>3</sub> will have an essentially linear dose-response curve with respect to activity of any individual PIP<sub>3</sub>-binding protein (although it would become non-linear for any process that depends on several such proteins). However, for binding proteins that also depend on PIP<sub>3</sub> “catalytically,” such as AKT, a far more dramatic effect might be expected on removal of the last few PIP<sub>3</sub> molecules per cell – perhaps accounting for the marked phenotypic differences between first- and second-generation *age-1*-null homozygotes (Ayyadevara et al., 2008).

We have now examined PIP<sub>3</sub> levels by quantitative immunofluorescence as well as functional assays, in first and second-generation *age-1(mg44)* homozygotes, comparing them to worms that bear wild-type or weaker *age-1* mutant alleles. We also have asked whether PI3K inhibitors can partially “phenocopy” *age-1* mutation in wild-type animals, to enhance longevity and stress tolerance.


## RESULTS

### PI3K IS WIDELY DISTRIBUTED IN WILD-TYPE *C. ELEGANS*, BUT IS NOT DETECTED OVER BACKGROUND IN *age-1*-NULL MUTANT WORMS

The *age-1(mg44)* allele encodes a truncated PI3K p110α protein, due to replacement of the Trp codon at position 387 (of 1146) by an amber stop codon (Ayyadevara et al., 2008). Antibody raised to the helical and kinase domains of AGE-1, lying downstream of (C-terminal to) the mutation, registered full-length enzyme as a diffuse cytoplasmic signal in virtually all cell types of wild-type *C. elegans* adults (Figures 1A,C). The same antibody, however, failed to detect AGE-1 protein in second-generation *age-1(mg44)* homozygotes, over the background seen in wild-type worms exposed only to the fluorescent secondary antibody (Figures 1B,C).

### PIP<sub>3</sub> IS SIGNIFICANTLY REDUCED IN FIRST-GENERATION *age-1(mg44)* HOMOZYGOTES, AND IS BELOW DETECTABLE LIMITS IN THEIR SECOND-GENERATION PROGENY

Despite the absence of full-length, catalytically active AGE-1 protein, it is possible that PIP<sub>3</sub> might be generated by a PI3K p110 of a different class, or *via* an alternative biosynthetic pathway. We therefore assessed PIP<sub>3</sub> levels, initially and most sensitively by *in situ* immunofluorescence but with confirmation by activity-based assays. Using a highly specific antibody against PIP<sub>3</sub> (Chen et al., 2002; Kharas et al., 2008), we found that *age-1(mg44)* second-generation homozygotes have no PIP<sub>3</sub>-specific immunofluorescence above background, i.e., their level is indistinguishable from negative control samples from which the primary antibody was omitted (Figure 2). In several replicate experiments comparing groups of day-8 adults (of which Figure 2 is typical), we observed 15–25% reductions in PIP<sub>3</sub> signal for worms carrying the weaker *hx546* allele of *age-1* (each *P* < 0.001 compared to wild-type), 60–75% reductions for first-generation *mg44* homozygotes



**FIGURE 1 | Immunodetection of AGE-1 protein (class-I PI3K catalytic subunit) in adult *C. elegans* of wild-type strain N2DRM (A) or second-generation *age-1(mg44)* homozygotes at adult age 3 days (B). Synchronized worms, fixed 14 h in 1% formaldehyde at 4°C, were permeabilized by successive exposures to 1% β-mercaptoethanol, 10-mM DTT, and 0.3% hydrogen peroxide. Primary antibody was goat**

anti-AGE-1 at 1:50 (Santa Cruz Biotech.), followed by rabbit anti-goat ALEXA680-tagged IgG at 1:200 (Invitrogen), imaged on an Olympus BX51 fluorescence microscope at 10×. The histograms (C) show mean fluorescence intensity, ±SEM, in two independent experiments. Each includes a negative control, staining of wild-type worms without primary antibody (rightmost bar).

(each  $P < 10^{-12}$ ), and essentially no signal above background in second-generation *mg44/mg44* adults ( $P < 10^{-12}$  relative to any group except negative controls). Because the upper bound of the 95% confidence interval for these “F2” *mg44*<sup>-/-</sup> worms is ~1.4% of the wild-type level, we infer that their PIP<sub>3</sub> level is reduced at least 70-fold relative to wild-type adults. PIP<sub>3</sub> levels were also assessed at several ages. Wild-type N2 worms showed maximal signal at 3 days of adult age (coinciding with peak fecundity) and fell to 35–40% of maximum at 6–10 days, whereas second-generation *mg44* homozygotes never differed significantly from background at adult ages 3, 5, or 10 days (data not shown).


Activity-based assays were used to confirm immunofluorescence quantitation of class-Iα PI3K, and of PIP<sub>3</sub>. PI3K activity is difficult to quantify in unstimulated cells, in which it is below the limits of detection, but it can be measured after induction by oxidative stress (Weinkove et al., 2006). We induced oxidative stress by exposing adult worms to 4 mM H<sub>2</sub>O<sub>2</sub> for 40 min at 20°C, in the presence of <sup>32</sup>PO<sub>4</sub><sup>-</sup>. Worms were then lysed and their PIPs isolated and resolved by thin-layer chromatography. PI3K activity was calculated as the ratio of <sup>32</sup>P incorporation coinciding with the position of a PIP<sub>3</sub> standard, to <sup>32</sup>P signal migrating with PIP<sub>2</sub>. As expected, no PIP<sub>3</sub> signal was detected in the absence of peroxide

stress. After H<sub>2</sub>O<sub>2</sub> exposure, it reached a measurable level (a ratio of 0.07) only for wild-type worms, but remained near-zero for worms carrying either *age-1* allele (Figure 3).

Similarly, we were able to confirm PIP<sub>3</sub> depletion in *age-1(mg44)* second-generation homozygotes, using a functional assay based on the requirement for PIP<sub>3</sub>-binding to bioactivate AKT via phosphorylation at Thr<sup>308</sup> (Stokoe et al., 1997). Antibodies recognizing unphosphorylated human AKT, or specific for AKT phosphorylated at Thr<sup>308</sup>, were used to evaluate the products of incubating bacterially synthesized human AKT with *C. elegans* lysates (Figure 4). The results support our immunofluorescence data, indicating the virtual absence of any PIP<sub>3</sub> in the very long-lived *mg44*-mutant worms, relative to wild-type. Dependence of the assay on endogenous PIP<sub>3</sub> was demonstrated by adding synthetic PIP<sub>3</sub> (Figure 4, rightmost bar).


#### **NEMATODE LIFESPAN AND PEROXIDE RESISTANCE ARE MODESTLY ENHANCED BY SEVERAL PI3K INHIBITORS, IN PARTICULAR PHOSPHATIDYLINOSITOL ANALOGS**

We tested a variety of PI3K inhibitors for the ability to extend nematode lifespan, in effect seeking a partial “pharmacopy” of the *age-1* phenotype. Neither wortmannin, LY294002, A66, nor




**FIGURE 2 | Immunofluorescence quantitation of PIP<sub>3</sub> in *C. elegans*.** Worms were permeabilized as for Figure 1 and incubated with mouse antibody to PIP<sub>3</sub> (Echelon), followed by a 1:200 dilution of secondary antibody, ALEXA594-labeled goat anti-mouse IgG (Invitrogen). Images (A–D), acquired on an Olympus BX51

microscope, were quantified with ImageJ and summarized in (E) for a typical experiment. Histogram bars show means  $\pm$  SEMs for 20–50 worms per group. Background, assessed without primary antibody, is shown (rightmost bar) but has not been subtracted. Worm ages are given in days (d) as adult.



**FIGURE 3 | *In vivo* <sup>32</sup>P-labeling of PIP<sub>2</sub> and PIP<sub>3</sub>.** Young adult worms were washed and incubated 16 h in phosphate-free medium to which 0.6 mCi <sup>32</sup>PO<sub>4</sub> were added. Where indicated, worms were exposed 45 min to 16-mM H<sub>2</sub>O<sub>2</sub>; lipids were extracted, chromatographed, and autoradiographed. Quantitative results (PIP<sub>3</sub> as a percent of the sum of PIP<sub>2</sub> and PIP<sub>3</sub>), determined by scintillation counting of excised spots, are given above the TLC image.



**FIGURE 4 | Functional assay of PIP<sub>3</sub> based on phosphorylation of AKT(Thr<sup>308</sup>).** Bacterially synthesized AKT, with an N-terminal His<sub>6</sub> tag, was added to cleared *C. elegans* lysates, and after 1 h at 20°C, was bound to AKT monoclonal antibody on AlphaBeads (PerkinElmer) in an AlphaScreen PI3K Assay (Echelon), and scored for also binding a tagged antibody to AKT(P-Thr<sup>308</sup>). Results were read on an Envision 2104 Microplate Reader (PerkinElmer). Error bars are standard deviations ( $N = 3$ ).


ZSTK474 (each tested at 1–10  $\mu$ M) increased the lifespan of wild-type worms (Table 1). However, GDC-0941 – reportedly the most avid p110 $\alpha$  inhibitor – at 1  $\mu$ M extended lifespan by 10% (nominally significant, Gehans–Wilcoxon  $P < 0.03$ ). We then tested four phosphatidylinositol analogs (PIAs) previously shown to be potent inhibitors of signal transduction *via* AKT activation (Gills et al., 2006, 2007; Memmott et al., 2008). PIA6 and PIA24 increased adult life span in two of three repeats, relative to PIA7 (inactive control) or DMSO vehicle-treatment. In the experiment shown (Figure 5), mean longevity was extended 10% ( $P < 0.05$ )

by PIA6, and nearly 14% by PIA24 ( $P < 0.015$ , Gehans–Wilcoxon log-rank test; Table 2).

We then compared PIAs 6, 12, and 24 to LY294002 or an inactive PIA, for their ability to extend survival of *C. elegans* exposed to a lethal oxidative stress, 5 mM hydrogen peroxide. PIAs 6 and 24 again conferred the greatest protection to wild-type worms, extending survival by 18 and 19%, respectively (each  $P < 10^{-6}$ ), while PIA12 initially increased peroxide survival 12% ( $P < 0.003$ ) and LY294002 by <1% (NS) relative to controls (Figure 6A;

**Table 1 | Effects of PI3K inhibitors on wild-type lifespan at 25°C.**

	DMSO	LY294002	Wortmannin	A66	GDC-0941	ZSTK474
		<b>1 μM</b>	<b>1 μM</b>	<b>1 μM</b>	<b>1 μM</b>	<b>1 μM</b>
Mean survival (days)	10.72	10.51	10.28	9.78	11.64	10.96
SD	2.31	2.66	2.91	2.26	2.32	2.24
SEM	0.31	0.55	0.69	0.49	0.42	0.41
N	54	23	17	22	30	29
% Of DMSO control		98.0	95.9	91.2	109.6	102.2
<i>P</i> , Gehans–Wilcoxon	–	–	–	–	<0.03	–
		<b>10 μM</b>	<b>10 μM</b>	<b>10 μM</b>	<b>10 μM</b>	<b>10 μM</b>
Mean survival (days)		9.80	10.83	9.97	10.97	9.60
SD		2.62	2.34	2.20	2.03	1.97
SEM		0.57	0.52	0.49	0.45	0.40
N		21	20	21	20	24
% Of DMSO control		91.4	101.0	93.0	102.3	89.6

**FIGURE 5 | Longevity survivals of wild-type (N2DRM) *C. elegans* maintained at 20°C on plates with phosphatidylinositol analogs (PIAs).**

Worms from synchronous cultures were selected as L4 larvae, and placed on 10-cm agar plates containing 1 μM of either PIA6, PIA24, or an inactive control, PIA7. They were transferred daily to identical plates on days 1–7 of adulthood to isolate them from their progeny, and transferred every 2–3 days thereafter. At each transfer, worms were scored as dead if they failed to move either spontaneously or in response to gentle prodding. Worms dying from desiccation due to stranding on the side walls of dishes, or from internal hatching of progeny, were censored at the midpoint of transfers between which death was discovered.

**Tables 3A,B).** In these experiments, PIAs generally conferred less (and less significant) protection to *age-1(hx546)* worms, although PIA12 appeared equally effective for either strain (**Figure 6B; Tables 3A,B**). When newly synthesized batches of PIAs 6 and 12 were subsequently tested (**Tables 3C,D**), PIA12 was more protective than PIA6, indicating that differences in these analogs may in large measure reflect purity and freshness of the compounds. LY294002 was only moderately effective at doses ranging from 1 to 20 μM, whereas the tested PIAs remained equally protective from 1 to 1000 μM (**Table 3** and additional data not shown).

**Table 2 | Effects of PIAs on wild-type (N2) lifespan at 20°C.**


	DMSO	PIA7	PIA6	PIA24
		<b>1 μM</b>	<b>1 μM</b>	<b>1 μM</b>
<b>EXPERIMENT 1</b>				
Mean survival (days)	18.8	19.2	20.3	20.5
SD	2.8	2.7	1.8	2.3
SEM	0.63	0.56	0.36	0.47
N	19	24	26	24
% (DMSO + PIA7)/2	–	–	106.8	108.0
<i>P</i> , Gehans–Wilcoxon	–	–	<0.10	<0.03
<b>EXPERIMENT 2</b>				
Mean survival (days)	17.3	16.6	18.2	18.8
SD	3.2	4.6	3.8	2.5
SEM	0.40	0.63	0.72	0.45
N	64	52	28	32
% (DMSO + PIA7)/2	–	–	109.9	113.5
<i>P</i> , Gehans–Wilcoxon	–	–	<0.06	<0.015
Combined Signif.:			<0.006	<0.0004

### PIP<sub>3</sub> ANALOGS INDUCE GENES THAT ARE POSITIVELY REGULATED BY INSULIN/IGF-1 SIGNALING

DAF-16 target genes such as those encoding SOD-3 and PEPCK are strikingly upregulated in *age-1(mg44)* worms, and somewhat less so in *age-1(hx546)* mutants – increases that are blocked when *daf-16* is deleted (Shmookler Reis et al., 2009; Tazearslan et al., 2009). The DAF-16 transcription factor was shown to mediate strong modulation of expression (by factors of 2 to >1000) by the *age-1* allele for a total of 64 genes (Ayyadevara et al., 2009; Tazearslan et al., 2009). SOD-3 is an Fe<sup>++</sup>/Mn<sup>++</sup> superoxide dismutase, believed to be mitochondrial and to protect against superoxide produced *via* the electron-transport chain; its mRNA is upregulated >9-fold in *age-1(mg44)*-F2 worms (Tazearslan et al., 2009). If PIA treatment, like *age-1* mutations, disrupts insulinlike signaling through DAF-16 activation, it should enhance transcription of *sod-3*. We treated young adult worms expressing a SOD-3::GFP fusion protein with several PIAs, each at 1 μM concentration. PIA24

**Table 3 | Protection against 5-mM peroxide by PI3K inhibitors at 20°C.**

<b>A. EXPERIMENT 1</b>						
	<b>DMSO</b>	<b>PIA7 1 μM</b>	<b>LY294002 1 μM</b>	<b>PIA6 1 μM</b>	<b>PIA12 1 μM</b>	<b>PIA24 1 μM</b>
<b>N2, wild-type</b>						
Mean survival (h)	6.8	6.6	6.7	7.9	7.5	8.0
SD	0.7	0.7	0.6	0.7	1.0	2.2
SEM	0.15	0.16	0.13	0.16	0.23	0.41
<i>N</i>	20	20	20	20	20	22
% of PIA7 control	–	–	101	118	112	119
<i>P</i> , Gehans–Wilcoxon	–	–	N.S.	<1E–6	0.002	<1E–6
<b>Age-1(hx546)</b>						
Mean survival (h)		9.8	10.8	10.0	11.0	9.6
SD		2.6	2.3	2.2	2.0	2.0
SEM		0.57	0.52	0.49	0.45	0.40
<i>N</i>		21	20	21	20	24
% of PIA7 control		–	96.5	116	112	112
<i>P</i> , Gehans–Wilcoxon		–	N.S.	0.0008	0.005	0.009
<b>B. EXPERIMENT 2</b>						
		<b>PIA7 10 μM</b>	<b>LY294002 10 μM</b>	<b>PIA6 10 μM</b>	<b>PIA6 (10 μM) + LY294002 (10 μM)</b>	
<b>N2, wild-type</b>						
Mean survival (h)		6.0	7.1	7.1	7.5	
SD		1.0	1.5	1.1	1.4	
SEM		0.15	0.24	0.17	0.23	
<i>N</i>		40	40	40	40	
% of PIA7 control		–	118	118	125	
<i>P</i> , Gehans–Wilcoxon		–	<1E–3	<1E–5	<1E–6	
<b>Age-1(hx546)</b>						
Mean survival (h)		8.3	8.6	9.0	9.0	
SD		1.5	1.2	1.0	1.1	
SEM		0.23	0.19	0.16	0.17	
<i>N</i>		40	40	40	40	
% of PIA7 control		–	103	107	107	
<i>P</i> , Gehans–Wilcoxon		–	NS	<0.04	<0.05	
<b>C. EXPERIMENT 3</b>						
	<b>PIA7 1 μM</b>	<b>PIA6 1 μM</b>	<b>PIA12 1 μM</b>		<b>PIA6 + LY 1 μM, 10 μM</b>	<b>PIA12 + LY 1 μM, 10 μM</b>
<b>N2, wild-type</b>						
Mean survival (h)	6.9	8.6	10.0		8.6	8.5
SD	1.6	1.6	1.1		1.7	1.7
SEM	0.25	0.25	0.17		0.26	0.27
<i>N</i>	40	40	40		40	40
% of PIA7 control	–	124	144		124	122
<i>P</i> , Gehans–Wilcoxon	–	<1E–5	<1E–12		<1E–4	<1E–4
<b>D. EXPERIMENT 4</b>						
	<b>PIA7 1 μM</b>	<b>PIA6 1 μM</b>	<b>PIA12 1 μM</b>	<b>PIA7 + LY 1 μM, 10 μM</b>	<b>PIA6 + LY 1 μM, 10 μM</b>	<b>PIA12 + LY 1 μM, 10 μM</b>
<b>N2, wild-type</b>						
Mean survival (h)	6.2	7.3	9.4	6.4	7.4	7.4
SD	1.32	1.5	1.2	1.4	1.8	1.6
SEM	0.30	0.33	0.28	0.32	0.40	0.35
<i>N</i>	20	20	20	20	20	20
% of PIA7 control	–	118	152	103	119	118
<i>P</i> , Gehans–Wilcoxon	–	<0.02	<1E–8	0.65	<0.04	<0.02




increased SOD-3::GFP levels by 26% after 48 h ( $P < 0.0002$ ), chiefly affecting diffuse global expression, whereas PIA6 and PIA12 produced increases of only 9% ( $P < 0.05$ ) and 6% (not significant) respectively, while LY294002 slightly reduced fluorescence (Figure 7, panels A–E,K). We tested putative PI3K inhibitors for effects on *pck-2*, the *daf-16* target gene encoding phosphoenolpyruvate carboxykinase (PEPCK), which is upregulated >8.5-fold in *age-1(mg44)*-F2 worms (Tazearslan et al., 2009). PEPCK is a key enzyme of metabolic regulation which extends lifespan and increases physical activity levels as well as metabolic rate when overexpressed in mice (Hakimi et al., 2007). Adult worms expressing a PEPCK::GFP fusion protein were treated with 1  $\mu$ M LY294002 or PIAs for 48 h. LY294002 increased PEPCK::GFP fluorescence by 25% ( $P < 0.01$  relative to PIA7 controls), while PIAs 6, 12, and 24 elicited increases of 39–41% (each  $P < 0.002$ ; Figure 7, panels F–J,L).

## DISCUSSION

Since *age-1(mg44)* F2-homozygous worms show no full-length PI3K catalytic subunit, it does not appear to be synthesized by either alternative-splicing or read-through routes that avoid the mutationally introduced stop codon. We note that the expression of other components of insulin/IGF-1 signaling are also suppressed at the transcript level in this strain, as are catalytic subunits for all three classes of PI3K (Tazearslan et al., 2009). This underscores the point that the unique survival phenotypes associated with this mutant may not derive entirely from direct effects of the *age-1* nonsense mutation, but may instead be indirect consequences.

These worms evidence no measurable PI3K activity, even when strongly induced by peroxide stress in a transiently starved state. Although measures of PI3K activity averaged zero, such negative findings (no detectable class-I PI3K enzyme or activity) are constrained by the limited sensitivity of the assays, to the rather weak conclusion that F2 *mg44*<sup>-/-</sup> worms have significantly less than half or one-fifth as much activity as wild-type (Figure 1C, left and right panels, respectively). In the PIP<sub>3</sub> immunoassay, however, the F2 mutant level had such a small variance that it was significantly below 1.4% of the wild-type value. In contrast, their “F1” homozygous parents had 40% of wild-type PIP<sub>3</sub> levels, which was far more than F2 progeny possessed ( $P < 10^{-15}$ ). These results are consistent with the hypothesis of maternal protection, wherein F1-homozygous worms acquire significant amounts of *age-1* mRNA, AGE-1 protein, and/or PIP<sub>3</sub>, from the oocytes formed in their heterozygous mothers. The *hx546* worms show higher levels of PIP<sub>3</sub> than *age-1* F1 or F2 worms, suggesting that they retain substantial kinase activity despite our failure to detect any by PI3K activity assay (Figure 3). Given that strong *age-1* mutation indirectly suppresses transcription of *pten*, encoding the PTEN phosphatase that opposes AGE-1/PI3K (Tazearslan et al., 2009), it is possible for steady-state PIP<sub>3</sub> levels to be reduced far less, in either *age-1* mutant, than PI3K itself.

We next determined the downstream consequences of chemical treatments thought to disrupt insulin/IGF-1 signaling, by monitoring global expression of SOD-3::GFP and PEPCK::GFP transgenic fusion proteins. The three active PIAs were of similar efficacy in stimulating PEPCK::GFP expression (Figure 7), and each was more effective than LY294002. When SOD-3::GFP fluorescence was assessed, however, LY294002 was actually inhibitory, and PIA24 was substantially more effective than either of the other PIAs. Since both *sod-3* and *pepck* are targets of the same FOXO transcription factor, DAF-16, it appears incongruous that the spectrum of drug activities should differ for these two endpoints. However, the tissue distribution differs between SOD-3 (globally expressed, with highest expression at the anterior tip, followed by the nerve ring just posterior to that, very similar to WormBase Expr8145 and Expr3925) and PEPCK (PCK-2, Expr6502 in WormBase: seen in adult intestine, reproductive organs, and vulval muscle, with lower expression in body-wall muscle); see Figure 7. Perhaps of even greater importance is the likelihood of multiple drug targets which differ among the PIAs (Gills et al., 2007). Differences between PIAs and more conventional PI3K inhibitors such as LY294002 are also expected, since PIAs



were designed to target the PIP<sub>3</sub>-binding site of AKT [and may also target other PIP<sub>3</sub>-binding sites (Gills et al., 2007) including that of PI3K], whereas LY294002, wortmannin, and many other PI3K inhibitors, instead target the ATP-binding pocket of the PI3K catalytic subunit (Walker et al., 2000). It is thus quite possible that “collateral targets” of these drugs differ among tissues, and some of these targets may interact differentially with SOD-3 vs. PEPCK reporters. We note that such unintended drug targets might include effects on translation and protein turnover components, which could then influence expression of reporters.

These same drugs also varied with respect to protection of N2 adults from peroxide stress (Figure 6). For a given synthesis, they followed the same rank order (PIA24 > PIA6 > PIA12) as lifespan and the induction of SOD-3, which contributes to oxidant protection. The *age-1(hx546)* mutation only blunted the protection by PIA24 to approximately the same level as PIA12 (Figure 6B), which may be explicable if PIA24 confers part of its oxidative stress resistance through interaction with AGE-1,

whereas the other PIAs act entirely *via* AGE-1-independent mechanisms (e.g., interaction with AKTs). LY294002 provided little or no benefit to either lifespan or peroxide survival; indeed, of all the drugs (other than PIAs) previously reported to inhibit PI3K, only GDC-0941 produced a nominally significant increase in *C. elegans* longevity, i.e.,  $P < 0.03$  without adjustment for multiple endpoints (Table 1). The absence of any short-term toxicity (or increased susceptibility to peroxide stress), for PIAs across a 1000-fold dose range, argues against a mechanism involving hormesis *via* deleterious drug effects. It remains to be seen whether drugs can be developed with greater specificity for class-I PI3K catalytic subunit, and whether those drugs will better recapitulate the extreme longevity and oxidative stress resistance of strong *age-1*-null mutations.

## MATERIALS AND METHODS

### STRAINS

Nematode strains were supplied by the *Caenorhabditis* Genetics Center (CGC, Minneapolis) and were maintained at 20°C



on 0.6% peptone NGM-agar plates seeded with *E. coli* strain OP50, as described (Ebert et al., 1993; Ayyadevara et al., 2001; Shmookler Reis et al., 2007). Cohorts were synchronized by alkaline hypochlorite lysis of parents (sparing eggs/larvae), and propagated on fresh nutrient-agar plates (Sulston and Hodgkin, 1988).

#### DETERMINATION OF LIFE SPAN

Nematodes, grown on NGM-agar plates containing 0.6% peptone, were harvested by rinsing off each plate with S buffer (0.1 M NaCl, 0.05 M potassium phosphate, pH 6.0) (Sulston and Hodgkin, 1988). Adults were allowed to settle, and then resuspended in alkaline hypochlorite (0.5 N NaOH, 1.05% hypochlorite; 5 min at 20°C). The recovered eggs (containing unenclosed larvae) were rinsed in S buffer and placed on fresh agar plates seeded with *E. coli* strain OP50. Survival cultures were established on 60-mm NGM-agar plates (Sulston and Hodgkin, 1988; Ebert et al., 1993; Ayyadevara et al., 2003) seeded with OP50. PI3K inhibitors, including LY294002, wortmannin, A66, ZSTK474, and GDC-0941 (Selleckchem, Houston, TX, USA) or phosphatidylinositol analogs (PIAs, from A. Kozikowski, University of Illinois, Chicago) dissolved in DMSO, were overlaid on plates to achieve final concentrations of 1, 2, or 10 μM. Worms were added 6 h later, 1 day after the L4/adult molt; 30–50 adults were transferred to each 60-mm dish. Worms were maintained at 20°C, and scored as alive, dead, or lost during daily transfer to fresh dishes. Worms were considered dead if they did not move either spontaneously or in response to touch; those lost (stranded on dish walls or beneath the agar) or killed by internal hatching of progeny (“bagging”) were censored at the midpoint of the time interval in which this occurred; worms inadvertently killed were censored at the time of the event.

#### HYDROGEN PEROXIDE STRESS TOLERANCE AFTER PIA TREATMENT

Adult worms [N2DRM or *age-1(hx546)*, as indicated] were synchronized by alkaline hypochlorite lysis of hermaphrodites; surviving embryos were transferred to fresh NGM-agar plates and allowed to mature. On reaching the L4 stage, worms were placed on fresh NGM-agar plates seeded with OP50 and overlaid with PIAs to achieve 1 μM. After 48 h, they were transferred to 24-well plates (20–25 worms per well) containing S medium (S buffer plus 0.5% cholesterol) and 5- or 7-mM hydrogen peroxide (Sigma) at 20°C, as previously described (Ayyadevara et al., 2005, 2008). Survival was scored as above, initially at 1-h intervals, until no worms remained alive. Assays, each comprising 20 or 40 worms, were performed two to six times per strain.

#### PIP<sub>3</sub> STAINING AND IMMUNOFLOUORESCENCE

N2DRM, *age-1(hx546)*, and *age-1(mg44)* worms were fixed at indicated ages by a modified Finney–Ruvkun protocol (Finney and Ruvkun, 1990). Briefly, worms were rinsed from plates in S buffer, rinsed again, and fixed at room temperature in S buffer containing 1% formaldehyde. The solution was frozen on dry ice and thawed overnight at 4°C with slow agitation. After centrifugation, 30 s at 2000 rpm, supernatant was aspirated and worms were washed twice with Tris-Triton buffer (“TTB,” comprising 0.1 M

Tris-Cl, pH 7.4; 10 mM EDTA; and 1% v/v Triton X-100), then incubated 2.5 h at 37°C in TTB plus 1% w/v β-mercaptoethanol to reduce disulfide bonds. Worms were washed twice in 25-mM borate buffer, pH 9.2, incubated 15 min at 37°C with borate plus 10-mM DTT, and exposed 15 min at 20°C to 0.3% H<sub>2</sub>O<sub>2</sub> in borate buffer. After rinsing in antibody B buffer [0.14 M NaCl; 50-mM sodium phosphate buffer, pH 7.9; 0.1% w/v bovine serum albumin (BSA); 0.1% v/v Triton X-100; 10-mM EDTA; and 0.05% w/v NaN<sub>3</sub>], they were incubated at 4°C overnight with mouse IgM antibody to PI<sub>(3,4,5)</sub>P<sub>3</sub> (Echelon Biosciences Inc.) diluted 1:50 in antibody A buffer (identical to B buffer but with 1% w/v BSA). Worms were washed in antibody B buffer (3 min × 30 min), then incubated 1.5 h at room temperature with ALEXA594-labeled donkey anti-mouse IgG (Molecular Probes) diluted 1:200 in antibody A buffer. After three 30-min washes in antibody B buffer, worms were counterstained with DAPI (Invitrogen) and mounted on slides with Prolong Gold Antifade Reagent (Invitrogen); images were captured with an Olympus BX51 fluorescence microscope.

#### EXPRESSION OF SOD-3::GFP AND PEPCK::GFP FOLLOWED BY PIA TREATMENT

PIAs were dissolved in DMSO, creating 20× stocks that produce final PIA concentrations of 1 or 10 μM in the agar plates. These solutions were overlaid on 60-mm dishes previously seeded with *E. coli* strain OP50. Adult worms were of strain TJ374 (zEx374) expressing SOD-3::GFP fusion protein, or strain BC10543 (sEx10543) expressing a PCK-2(R11A5.4)::GFP fusion protein. They were synchronized by alkaline hypochlorite lysis of hermaphrodites, and surviving embryos were transferred to fresh NGM-agar plates. Young adults (post-L4 molt) were transferred to NGM-agar plates with PIAs. After 48 h, adult worms were collected, washed three times in S buffer, and fixed in 1% formaldehyde. Worms were mounted on slides under a coverslip, and fluorescence images were taken using an Olympus BX51 microscope.

#### IN VIVO PIP<sub>3</sub> ASSAY

Wild-type and *age-1* mutant worms were collected and washed in phosphate-free RPMI-1640 medium, then labeled at 20°C with 1 mCi/ml [<sup>32</sup>P]-orthophosphate for 16 h in phosphate-free RPMI-1640 medium. <sup>32</sup>P-labeled worms were then washed once in phosphate-free RPMI-1640 medium, and lipids were extracted and separated by thin-layer chromatography according to a published procedure (Weinkove et al., 2006). After autoradiography, spots were scraped from the chromatograph and β emissions quantified in a scintillation counter (Beckman).

#### ACKNOWLEDGMENTS

We thank Alan Kozikowski for the generous gift of his synthetic phosphatidylinositol analogs (PIA6, PIA7, PIA12, and PIA24); Selleckchem for kindly providing samples of PI3K inhibitors A66, ZSTK474, and GDC-0941; Dawn N. Mercer and Kenda Evans of PerkinElmer, for expert guidance in performing the AlphaScreen assays (Figure 4); and the US Department of Veteran Affairs for infrastructure and support (Sr. Research Career Scientist Award to Robert J. Shmookler Reis).

## REFERENCES

- Ayyadevara, S., Alla, R., Thaden, J. J., and Shmookler Reis, R. J. (2008). Remarkable longevity and stress resistance of nematode PI3K-null mutants. *Aging Cell* 7, 13–22.
- Ayyadevara, S., Ayyadevera, R., Hou, S., Thaden, J. J., and Shmookler Reis, R. J. (2001). Genetic mapping of quantitative trait loci governing longevity of *Caenorhabditis elegans* in recombinant-inbred progeny of a Bergerac-BO×RC301 interstrain cross. *Genetics* 157, 655–666.
- Ayyadevara, S., Ayyadevera, R., Vertino, A., Galecki, A., Thaden, J. J., and Shmookler Reis, R. J. (2003). Genetic loci modulating fitness and life span in *Caenorhabditis elegans*: categorical trait interval mapping in CL2a×Bergerac-BO recombinant-inbred worms. *Genetics* 163, 557–570.
- Ayyadevara, S., Engle, M. R., Singh, S. P., Dandapat, A., Lichti, C. F., Benes, H., et al. (2005). Lifespan and stress resistance of *Caenorhabditis elegans* are increased by expression of glutathione transferases capable of metabolizing the lipid peroxidation product 4-hydroxynonenal. *Aging Cell* 4, 257–271.
- Ayyadevara, S., Tazearslan, C., Alla, R., Bharill, P., Siegel, E., and Shmookler Reis, R. J. (2009). *C. elegans* PI3K mutants reveal novel genes underlying exceptional lifespan and stress resistance. *Aging Cell* 8, 706–725.
- Berdichevsky, A., Viswanathan, M., Horvitz, H. R., and Guarente, L. (2006). *C. elegans* SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. *Cell* 125, 1165–1177.
- Boss, W. F., and Im, Y. J. (2012). Phosphoinositide signaling. *Annu. Rev. Plant Biol.* 63, 409–429.
- Castillo, S. S., Brognard, J., Petukhov, P. A., Zhang, C., Tsurutani, J., Granville, C. A., et al. (2004). Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. *Cancer Res.* 64, 2782–2792.
- Chen, R., Kang, V. H., Chen, J., Shope, J. C., Torabinejad, J., Dewald, D. B., et al. (2002). A monoclonal antibody to visualize PtdIns(3,4,5)P(3) in cells. *J. Histochem. Cytochem.* 50, 697–708.
- Cutillas, P. R., Khwaja, A., Graupera, M., Pearce, W., Gharbi, S., Waterfield, M., et al. (2006). Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. *Proc. Natl. Acad. Sci. U.S.A.* 103, 8959–8964.
- Dragoi, A. M., Fu, X., Ivanov, S., Zhang, P., Sheng, L., Wu, D., et al. (2005). DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. *EMBO J.* 24, 779–789.
- Ebert, R. H., Cherkasova, V. A., Dennis, R. A., Wu, J. H., Ruggles, S., Perrin, T. E., et al. (1993). Longevity-determining genes in *Caenorhabditis elegans*: chromosomal mapping of multiple noninteractive loci. *Genetics* 135, 1003–1010.
- Echard, A. (2012). Phosphoinositides and cytokinesis: the “PIP” of the iceberg. *Cytoskeleton (Hoboken)* 69, 893–912.
- Finney, M., and Ruvkun, G. (1990). The unc-86 gene product couples cell lineage and cell identity in *C. elegans*. *Cell* 63, 895–905.
- Franke, T. E., Kaplan, D. R., and Cantley, L. C. (1997). PI3K: downstream AKTion blocks apoptosis. *Cell* 88, 435–437.
- Gambhir, A., Hangyas-Mihalyne, G., Zaitseva, I., Cafiso, D. S., Wang, J., Murray, D., et al. (2004). Electrostatic sequestration of PIP2 on phospholipid membranes by basic/aromatic regions of proteins. *Biophys. J.* 86, 2188–2207.
- Gills, J. J., Castillo, S. S., Zhang, C., Petukhov, P. A., Memmott, R. M., Hollingshead, M., et al. (2007). Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. *J. Biol. Chem.* 282, 27020–27029.
- Gills, J. J., Holbeck, S., Hollingshead, M., Hewitt, S. M., Kozikowski, A. P., and Dennis, P. A. (2006). Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. *Mol. Cancer Ther.* 5, 713–722.
- Hakimi, P., Yang, J., Casadesu, G., Massillon, D., Tolentino-Silva, F., Nye, C. K., et al. (2007). Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. *J. Biol. Chem.* 282, 32844–32855.
- Hawkins, P. T., Anderson, K. E., Davidson, K., and Stephens, L. R. (2006). Signalling through Class I PI3Ks in mammalian cells. *Biochem. Soc. Trans.* 34, 647–662.
- Kharas, M. G., Janes, M. R., Scarfone, V. M., Lilly, M. B., Knight, Z. A., Shokat, K. M., et al. (2008). Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. *J. Clin. Invest.* 118, 3038–3050.
- King, J. S., Teo, R., Ryves, J., Reddy, J. V., Peters, O., Orabi, B., et al. (2009). The mood stabiliser lithium suppresses PIP3 signalling in *Dicystostelium* and human cells. *Dis. Model. Mech.* 2, 306–312.
- Kozikowski, A. P., Sun, H., Brognard, J., and Dennis, P. A. (2003). Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. *J. Am. Chem. Soc.* 125, 1144–1145.
- Mayinger, P. (2012). Phosphoinositides and vesicular membrane traffic. *Biochim. Biophys. Acta* 1821, 1104–1113.
- Memmott, R. M., Gills, J. J., Hollingshead, M., Powers, M. C., Chen, Z., Kemp, B., et al. (2008). Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. *Cancer Res.* 68, 580–588.
- Morris, J. Z., Tissenbaum, H. A., and Ruvkun, G. (1996). A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in *Caenorhabditis elegans*. *Nature* 382, 536–539.
- Pettitt, T. R., Dove, S. K., Lubben, A., Calamini, S. D., and Wakelam, M. J. (2006). Analysis of intact phosphoinositides in biological samples. *J. Lipid Res.* 47, 1588–1596.
- Plum, L., Ma, X., Hampel, B., Balthasar, N., Coppari, R., Munzberg, H., et al. (2006). Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. *J. Clin. Invest.* 116, 1886–1901.
- Schultz, R. M., Merriman, R. L., Andis, S. L., Bonjouklian, R., Grindey, G. B., Rutherford, P. G., et al. (1995). In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. *Anti-cancer Res.* 15, 1135–1139.
- Semba, S., Itoh, N., Ito, M., Harada, M., and Yamakawa, M. (2002). The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. *Clin. Cancer Res.* 8, 1957–1963.
- Sester, D. P., Brion, K., Trieu, A., Goodridge, H. S., Roberts, T. L., Dunn, J., et al. (2006). CpG DNA activates survival in murine macrophages through TLR9 and the phosphatidylinositol 3-kinase-Akt pathway. *J. Immunol.* 177, 4473–4480.
- Shmookler Reis, R. J., Bharill, P., Tazearslan, C., and Ayyadevara, S. (2009). Extreme-longevity mutations orchestrate silencing of multiple signaling pathways. *Biochim. Biophys. Acta* 1790, 1075–1083.
- Shmookler Reis, R. J., Kang, P., and Ayyadevara, S. (2007). Quantitative trait loci define genes and pathways underlying genetic variation in longevity. *Exp. Gerontol.* 41, 1046–1054.
- Shilbans, V., Wu, M., and Burstein, D. E. (2008). Current overview of the role of Akt in cancer studies via applied immunohistochemistry. *Ann. Diagn. Pathol.* 12, 153–160.
- Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., et al. (1997). Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* 277, 567–570.
- Sulston, J., and Hodgkin, J. (1988). “Methods,” in *The Nematode Caenorhabditis elegans*, ed. W. B. Wood (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press), 587–606.
- Tazearslan, C., Ayyadevara, S., Bharill, P., and Shmookler Reis, R. J. (2009). Positive feedback between transcriptional and kinase suppression in nematodes with extraordinary longevity and stress resistance. *PLoS Genet.* 5:e1000452. doi:10.1371/journal.pgen.1000452
- Tissenbaum, H. A., and Ruvkun, G. (1998). An insulin-like signaling pathway affects both longevity and reproduction in *Caenorhabditis elegans*. *Genetics* 148, 703–717.
- Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *J. Biol. Chem.* 269, 5241–5248.
- Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., et al. (2000). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. *Mol. Cell* 6, 909–919.
- Weinkove, D., Halstead, J. R., Gems, D., and Divecha, N. (2006). Long-term starvation and ageing induce AGE-1/PI 3-kinase-dependent translocation of DAF-16/FOXO to the cytoplasm. *BMC Biol.* 4:1. doi:10.1186/1741-7007-4-1

- Wu, Z. L., O'Kane, T. M., Connors, T. J., Marino, M. J., and Schaffhauser, H. (2008). The phosphatidylinositol 3-kinase inhibitor LY 294002 inhibits GlyT1-mediated glycine uptake. *Brain Res.* 1227, 42–51.
- Wymann, M. P., and Schultz, C. (2012). The chemical biology of phosphoinositide 3-kinases. *Chembiochem* 13, 2022–2035.
- Yi, H. K., Kim, S. Y., Hwang, P. H., Kim, C. Y., Yang, D. H., Oh, Y., et al. (2005). Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. *Biochem. Biophys. Res. Commun.* 330, 760–767.
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Received: 05 January 2013; accepted: 01 March 2013; published online: 28 March 2013.
- Citation: Bharill P, Ayyadevara S, Alla R and Shmookler Reis RJ (2013) Extreme depletion of PIP<sub>3</sub> accompanies the increased life span and stress tolerance of PI3K-null *C. elegans* mutants. *Front. Genet.* 4:34. doi: 10.3389/fgene.2013.00034
- This article was submitted to *Frontiers in Genetics of Aging*, a specialty of *Frontiers in Genetics*.
- Copyright © 2013 Bharill, Ayyadevara, Alla and Shmookler Reis. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.